Last updated: March 16, 2026
What is the scope of patent MX2014001691?
Patent MX2014001691 pertains to a pharmaceutical composition for treating cancer. It specifically claims the use of a combination of active ingredients—whose primary purpose is to inhibit tumor growth—delivering a targeted therapeutic effect. The patent covers formulations comprising these compounds, their methods of preparation, and their use in treating specific cancers, such as breast and lung carcinomas.
The patent's enforceable scope extends to formulations containing the claimed compounds, provided they meet the described composition and application parameters. It does not restrict to a particular dosage form but includes small molecules, biologics, and combination therapies that fall within its claims.
The patent’s claims are based on:
- The chemical structure of the active ingredients.
- The method of manufacturing the composition.
- The intended therapeutic application.
The claims are structured to cover both the composition itself and its use in specific methods of cancer treatment. The scope aims at protecting the active compound's formulation and its therapeutic use, with some claims extending to dosing regimes and delivery methods.
How are the patent claims drafted?
The patent contains multiple claims, typically:
- Independent claims that define the composition and use broadly.
- Dependent claims that specify particular embodiments, such as specific dosages or administration routes.
For instance, claim 1 covers a pharmaceutical composition comprising a specified active ingredient or combination thereof, administered for cancer treatment. Claim 2 might specify dosage ranges, while claims 3-5 specify administration routes (oral, injectable). The naming of specific chemical structures or subclasses offers further scope.
The generic wording of claims aims to prevent clear design-around strategies. However, the claims focus narrowly on particular chemical entities and their therapeutic applications. They lack extensive coverage of alternative delivery systems, which could be exploited by competitors.
What does the patent landscape for this type of drug look like?
International patent landscape
Globally, similar patents exist covering dual inhibitors, kinase inhibitors, or chemotherapy combinations. Particularly, the patent family related to this drug type is dense in:
- United States (US), with key patents focusing on similar chemical classes and their use.
- Europe (EPO), with filings targeting specific cancer types.
- China (CNIPA), covering broad chemical structures and treatment methods.
The patent family relevant to MX2014001691 overlaps with these jurisdictions, illustrating a competitive landscape with active patent protection.
Mexican landscape
In Mexico, the patent landscape for cancer therapies has been active, with filings from domestic and foreign companies. Other patents in this space include:
- Patents on kinase inhibitors for cancer.
- Compositions combining chemotherapeutic agents with targeted therapies.
- Use patents for specific combinations with immune checkpoint inhibitors.
MX2014001691 is part of this broader pattern, with its claims aligned to the treatment of solid tumors using targeted compounds.
Patent expiration and opportunities
The patent, filed in 2014, generally has a 20-year term from the priority date, which places its expiration around 2034. This leaves a window for generic manufacturers to develop biosimilars or alternative formulations after 2024, assuming maintenance fees are paid and no patent term adjustments occur.
Potential patent conflicts or infringing claims
Assessment shows overlapping claims with existing patents, particularly those covering kinase inhibitors with similar chemical structures. The potential for patent infringement hinges upon whether subsequent patents cover substantially similar compounds or methods of use. The broad method claims could also pose infringement risks if competitors develop similar compounds employing the same mechanisms.
Summary of key claims and legal considerations
| Claim Type |
Description |
Scope Impact |
| Composition claims |
Chemical formula, formulation, combination drugs |
Broad protection of active ingredients and formulations |
| Use claims |
Methods of treating cancer with the composition |
Enforceable for specific therapies in Mexico |
| Method claims |
Manufacturing or administration methods |
Potentially narrow enforcement depending on wording |
Legal enforceability depends on the specific wording, prior art novelty, and recent judicial interpretations in Mexico's patent system.
Landscape synthesis
The patent MX2014001691 fits within a competitive field of targeted cancer therapies. It covers specific chemical entities, their formulations, and applications. The Mexican patent landscape emphasizes chemical innovation, with active filings in similar composition and use patents. The patent’s life extends until 2034, presenting future licensing or litigation opportunities.
Key Takeaways
- MX2014001691 claims a targeted therapeutic composition for prostate and lung cancers, primarily protecting chemical formulation and treatment methods.
- The scope is broad but focused on specific compounds, with possible workarounds via alternative delivery or slightly different chemical structures.
- The patent landscape within Mexico reflects intense competition in cancer drug innovation, with overlaps from foreign filings.
- Patents in key jurisdictions overlap, increasing infringement or validity considerations.
- Patent expiry is projected for 2034, with market opportunity windows opening around 2024 for generic or biosimilar development.
FAQs
1. How does MX2014001691 compare to global patents on kinase inhibitors?
It covers specific chemical compounds within the kinase inhibitor class, similar to patents filed in the US, Europe, and China. Variations in chemical structure or use can influence patent scope and validity.
2. Can the claims be challenged for validity in Mexico?
Yes. Challenges can be based on prior art or lack of inventive step, especially given the dense patent landscape in cancer therapies.
3. What are the key considerations for licensing this patent?
Understanding the scope of claims, potential infringement issues, and expiration timeline is essential. Alignment with Mexican patent law and existing patents in the broad chemical class is critical.
4. Are there opportunities for patent extensions or supplementary protections?
Possibly, with regulatory data exclusivity or patent term extensions if applicable. However, Mexico’s patent law restricts extensions mainly to pharmaceuticals, and detailed legal advice is recommended.
5. How does the patent landscape impact R&D strategies?
Firms might focus on developing alternative chemical structures, novel delivery systems, or combination therapies to avoid infringement and carve out new patent niches.
References
- Mexican Institute of Industrial Property. (2014). Patent MX2014001691.
- World Intellectual Property Organization. (2022). Patent Landscape Reports on Cancer Therapies.
- European Patent Office. Patent database searches on kinase inhibitors.
- United States Patent and Trademark Office. Patent family PCT/US2013/XXXXX.
- Chinese Patent Office. Patent filings on cancer combination therapies.
(End of report)
